Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

The study will have two treatment groups, evaluating two Degarelix doses. First dose is the initial dose followed by a maintenance dose given every three months. The initial dose given to suppress the testosterone level and the three month maintenance dose to maintain the suppressed testosterone level over one year of treatment.

Key facts

Study ID
NCT00468286
Run by
Ferring Pharmaceuticals
People needed
133
Starts
2007-05-01
Expected to finish
2008-08-01
Last updated by the study team
2011-03-23

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.